Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Roche anticipates...

    Roche anticipates quicker US approval for new multiple sclerosis drug

    Written by savita thakur thakur Published On 2016-06-29T12:49:43+05:30  |  Updated On 29 Jun 2016 12:49 PM IST
    Roche anticipates quicker US approval for new multiple sclerosis drug

    Zurich : Roche's new multiple sclerosis (MS) drug could be approved in the United States this year, earlier than previously forecast, the Swiss drugmaker said, after winning the U.S. regulator's priority review status for the medicine.


    The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) accepted marketing applications for Roche's Ocrevus medicine, for both the relapsing-remitting and primary-progressive forms of MS, the company said in a statement.


    With FDA fast-track review, Roche said U.S. approval for Ocrevus now could come by Dec. 28, faster than the company's previous estimate of early 2017.


    "It offers the hope that soon we'll be able to bring ocrelizumab to patients," said Paulo Fontoura, who heads Roche's clinical development program in neuroscience, in an interview, referring to the chemical name for Ocrevus.


    "We feel strongly based on the data that this is a medicine that has the potential to really change the way MS is being treated right now."


    Ocrevus' approval in Europe will likely stretch into the third quarter of 2017, Fontoura said.


    Roche submitted its application for Ocrevus last year, before the EMA initiated its own fast-track "Prime" approval process to cut the time it takes promising new medicines to get to market.


    "That's a very new process for the EMA," Fontoura said. "It hasn't really had an impact yet."


    Winning regulators' backing for Ocrevus is a pivotal part of Roche's strategy to develop new drugs for cancer and other diseases to replace revenue from older medicines such as Rituxan whose patents are expiring, leaving them exposed by late 2017 to cheaper biosimilar drug copies.


    MORE OPTIMISTIC


    In an interview last week, Chief Executive Severin Schwan said he had grown steadily more optimistic that his company's new drugs would boost revenue even amid the biosimilars threat.


    Ocrevus sales could hit 3.7 billion Swiss francs ($3.8 billion) by 2022, according to Reuters data.


    Roche has previously said late-stage trials with Ocrevus show it works better than rival drugmaker Merck's Rebif in patients suffering from relapsing MS.


    The drug, administered by intravenous infusion every six months, would be the first approved treatment for the primary-progressive form of the disease.


    About 85 percent of those diagnosed with MS suffer from relapsing-remitting MS, while 10 percent suffer from primary-progressive MS.

    approvalbiosimilar drugcancerEMAEuropean Medicines AgencyMSmultiple sclerosisMultiple Sclerosis DrugPaulo FontouraRocheSeverin SchwanSwiss francsUS Food & Drug AdministrationUSFDA
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok